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Abstract
GABAA receptors that contain the α5-subunit (α5GABAA) exhibit high sensitivity to GABA
and confer tonic activity. Moreover, α5GABAA receptors have been associated with brain
inflammation, in which microglia are activated. This study investigates the role of α5GABAA
receptors in microglial activation. Immunohistochemistry revealed that in response to
intraperitoneal lipopolysaccharide (LPS), α5-subunit null mice exhibited significantly higher
expression of IL-1β in hippocampal microglia. Neuronal-glial co-cultures treated with the
α5GABAA receptor inverse agonist L655,708 drastically increased microglial IL-1β
expression. Surprisingly, ELISA of media from L655,708-treated co-cultures showed a
considerably lower concentration of IL-1β. Treating cultured primary astrocytes with LPS
increased IL-1β secretion, which was reduced by co-treatment with L655,708. Cultured
primary microglia did not respond to LPS/L655,708. When grown in LPS-primed astrocytic
conditioned media, primary microglia secreted IL-1β, which increased in the presence of
L655,708. These data suggest that α5GABAA receptors in astrocytes indirectly modulate
microglial activation.
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Chapter 1: Introduction

Microglial cells (microglia) play critical roles in the processes of neuronal network
formation, maintaining CNS homeostasis, innate immunity and neurodegeneration at
different stages of life. As innate immune cells, microglia can be activated by diverse
infection-related

molecules

such

as

the

Gram-negative

bacterial

endotoxin

lipopolysaccharide (LPS). The activity and function of microglia are also effectively
regulated by various soluble factors including cytokines and neurotransmitters. Gammaaminobutyric acid (GABA) is a primary neurotransmitter in the central nervous system
(CNS). Recent studies have reported that type-A GABA (GABAA) receptors are expressed
on monocytes, macrophages and possibly on microglia. Moreover, a new study indicates that
the activity of the α5-subunit-containing GABAA (α5GABAA) receptor is associated with
brain inflammation (Wang et al., 2012). However, the mechanism by which α5GABAA
receptors regulate the innate immunity of the CNS and the process of neuroinflammation
remains largely unclear. My thesis aims to investigate the role of α5GABAA receptors in the
regulation of microglial activation by LPS, as well as related cellular and molecular
mechanisms. In this chapter, I will provide a brief overview of the current literature regarding
microglia activation in response to inflammatory stimulants, with a focus on the role of
GABA signaling in the regulation of inflammation.

1.1 Microglia and Neuroinflammation
Microglia are the resident macrophages of the CNS, playing a pivotal role in CNS innate
immunity. Microglia make up ~15-20% of brain cells in the healthy adult brain (Polazzi and
Monti, 2010; Rojo et al., 2010). Originally from mesodermal origin, myeloid progenitors
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migrate into the brain during embryonic development where they settle and further
differentiate into microglia (Chan et al., 2007). Since the blood-brain barrier (BBB) largely
prevents immune cell infiltration, microglia serve as the major immune cells in the brain
although other cell types such as astrocytes and neurons have immunomodulatory functions
(Dong and Benveniste, 2001; Veerhuis et al., 2011). However, breakdown of the blood brain
barrier can occur (e.g. multiple sclerosis), coinciding with peripheral immune cell infiltration
(Engelhardt, 2006; Raine et al., 1990).

1.1.1 Microglial Activity
Microglia constantly survey their surrounding area and readily react to damage in the brain.
In the healthy brain, microglia remain in a “resting” state, while they become “activated”
when disruptions of brain homeostasis occur (Kettenmann et al., 2011). Although termed
“resting”, microglia in this state are still functioning in an important role. Resting microglia
are active in the sense that they are always surveying the brain parenchyma. Resting
microglia are characterized by having extended, branched processes from a small cell body;
this is also known as a ramified morphology (Kettenmann et al., 2011). In the absence of
stimulatory signals, microglia retain a ramified, resting state and have minimal phagocytic
ability (abd-el-Basset and Fedoroff, 1995; Ribes et al., 2009; Sivagnanam et al., 2010).
Regular monitoring of the brain involves the motile microglial processes, which are used to
constantly scrutinize a specific, non-overlapping territory monitoring for changes in
homeostasis such as injury signals known as pathogen-associated molecular patterns and
damage-associated molecular patterns (PAMPs/DAMPs) (Bianchi, 2007; Ohsawa and
Kohsaka, 2011). Increased microglia process movement has been linked to microglia
activation (Fontainhas et al., 2011; Nimmerjahn et al., 2005).
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The morphology and activity of microglia is subject to regulation by other cell types in the
brain such as astrocytes and neurons. Studies have indicated that astrocytes can secrete
cytokines such as macrophage colony-stimulating factor (M-CSF), transforming growth
factor-β (TGF-β), and granulocyte/macrophage colony-stimulating factor (GM-CSF), which
keep microglia in a resting state showing ramified processes (Schilling et al., 2001). Neurons
also play a role in the control of microglial activity. For example, neurons constitutively
express CD200, an immunoglobin superfamily molecule that is on the membrane surface.
CD200 interacts with the CD200 receptor expressed on microglia, resulting in an inhibitory
effect (Hoek et al., 2000). Another prominent factor secreted by neurons is the chemokine
CX3CL1/fractalkine, which can exist as a membrane bound or a soluble chemokine that
recognizes its receptor CX3CR on microglia protecting against microglial neurotoxicity
(Cardona et al., 2006; Cook et al., 2001). In addition, microglia express neurotransmitter
receptors. For instance, it is reported that activating GABAB receptors expressed on
microglia attenuates their activity (Kuhn et al., 2004).
Microglia can become activated from a resting state in response to various stimulating
signals (Fig. 1.1). These signals include neuronal injuries, infection, inflammation or other
homeostatic disruptions. Upon activation, microglia undergo morphological and functional
changes. The morphological changes include the retraction of their ramified processes back
to the cell body. Fully activated microglia have been described as amoeboid, which allows
for increased mobility and promotes phagocytic activity (Dheen et al., 2007; Kettenmann et
al., 2011). On the other hand, the functional changes of activated microglia include the
increased production and secretion of cytotoxic factors and pro-inflammatory cytokines
(Smith et al., 2012). It has been well documented that activated microglia produce cytokines,
chemokines, prostaglandins, excitatory amino acids, quinolinic acid, complement proteins,
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reactive oxygen intermediates and nitric oxide (Nakajima and Kohsaka, 2001). Prolonged
microglial activation has been linked to various neurodegenerative diseases such as multiple
sclerosis, Alzheimer’s disease, Parkinson’s disease, gliomas and others (Chao et al., 1992;
Smith et al., 2012).

Figure 1.1 Resting, ramified microglia become activated in response to various “injury”
signals in/to the brain. This leads to phenotypic (e.g. production of cytokines) and
morphological changes (e.g. retraction of processes).

Like other phagocytes, microglia also express phagocyte-specific proteins, such as cluster of
differentiation-11b (CD11b), a member of the β2-integrin family expressed on the surface of
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phagocytes. CD11b plays a role in microglia activity. Together with CD18, CD11b forms
the MAC-1 receptor also known as the complement component receptor 3 (CR3). This
receptor is able to bind complement C3bi and intercellular cell adhesion molecule-1 (ICAM1) (Reichert and Rotshenker, 2003; Ross and Vetvicka, 1993; Ueda et al., 1994), playing a
fundamental role in microglial phagocytosis. Microglia have also been reported to utilize
CD11b for developmental neuronal apoptosis. (Wakselman et al., 2008). The surface
expression of CD11b is up-regulated in activated microglia (Le Cabec et al., 2002; Roy et al.,
2006) and reported stimuli that increase CD11b expression include LPS and nitric oxide
(NO) (Fenton and Golenbock, 1998; Roy et al., 2006).

1.1.2 Activation of microglia by LPS
LPS consists of a polysaccharide (sugar) chain and a lipid moiety, known as lipid A, which is
in the outer membrane of Gram-negative bacteria. Although LPS cannot pass the blood brain
barrier in most circumstances, a small amount of LPS may enter the brain (Lacroix et al.,
1998). Like macrophages, microglia are highly sensitive to LPS and exhibit robust activation
(Singh and Jiang, 2004). Thus, LPS is used as the model stimulant to study activated
microglia in vitro (Hanisch and Kettenmann, 2007). LPS binds to soluble LPS binding
protein (LBP) and is recognized by CD14+ immune cells. The bound LPS is then recognized
by the toll-like receptor 4 (TLR4), which in turn activates inflammatory signaling pathways
including NF-κB and MAPK pathways (Guha and Mackman, 2001). These signaling
pathways are able to induce gene transcription of pro-inflammatory cytokines (e.g. IL-1β,
TNF-α) in CD14+/TLR4+ expressing cell types, especially in macrophages and microglia
(Guha and Mackman, 2001; Woodroofe et al., 1991).
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As a large molecule, LPS does not readily pass through the intact blood brain barrier and is
unlikely able to directly activate microglia in most areas of the CNS (Banks and Robinson,
2010; Rothwell and Hopkins, 1995). However, following systemic administration of LPS,
vigorous inflammatory reactions occur in the brain showing activated microglia (Dantzer et
al., 2008; Yirmiya and Goshen, 2011). There are several ways that systemic inflammation
triggered by LPS can translate into CNS inflammation. LPS administration results in
increased production of cytokines by peripheral immune cells and the elevated cytokines
(including IL-1β) in the circulation can pass through the blood brain barrier, although these
transport mechanisms may be inefficient (Banks et al., 1995; Quan et al., 1998). The
circumventricular organs (CVOs), choroid plexus, and leptomeninges are regions in the brain
that are termed “leaky” as they do not have a blood brain barrier. Moreover in response to
systemic inflammation, an upregulated expression of the LPS receptor CD14 occurs in these
structures, and in microglia throughout the brain. This suggests that microglia are capable of
responding indirectly to LPS in systemic inflammation (Hashimoto et al., 1991; Laflamme
and Rivest, 2001; Rivest, 2003). The vagus nerve also provides a means of transducing a
negative regulatory response to systemic inflammation as subdiaphragmatic vagotomy
reduced the immune response in the CNS in response to LPS or IL-1β (Bluthe et al., 1994;
Konsman et al., 2000). However, this mechanism largely depended on the dose of the
stimulus (Hansen et al., 2000; Hansen et al., 2001). Another way that systemic inflammation
can induce an inflammatory signal in the brain is through the activation of endothelial cells
on the blood-brain barrier. In response to LPS or circulating cytokines in the periphery,
cerebral vascular cells produce prostaglandin E2, a small lipophilic eicosanoid, which readily
diffuses into the brain parenchyma to mediate inflammation in the brain. (Ek et al., 2001;
Lacroix and Rivest, 1998).
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1.1.3 Inflammatory mediators secreted by activated microglia
As stated above, LPS activates microglia via NFκB and/or MAP kinase pathways (Kim et al.,
2004; Simi et al., 2002), which in turn initiate the production of various inflammatory
factors, such as interleukin-1β, cyclooxygenase-2, inducible nitric oxide synthase, and
monocyte chemoattractant-1.

1.1.3.1

Interleukin-1β

The IL-1 gene family consists of three products: IL-1α, IL-1β and IL-1 receptor antagonist
(IL-1Ra) (Dinarello, 1996).

IL-1α is an autocrine growth factor that is constitutively

produced but not induced in stimulated blood monocytes. (Dinarello, 2009; Lonnemann et
al., 1989; Schindler et al., 1990). IL-1β serves as a widespread proinflammatory cytokine that
plays a major role in mediating immune responses to infection, injury, and local and systemic
inflammation (Dinarello, 1998). The soluble IL-1Ra binds to IL-1 receptors, competing
against IL-1β. Therefore, IL-1Ra serves as an attenuating signal for IL-1β and is a
mechanism of controlling IL-1β’s effects.
Both IL-1α and IL-1β are recognized by several IL-1 receptors, although the two main
receptors are IL-1 type I receptor (IL-1RI) and IL-1 type II receptor (IL-1RII). IL-1RI is
expressed ubiquitously on multiple cell types and its cytosolic domain closely resembles the
domains of Toll-like receptors (TLR), a receptor for innate immunity. Therefore, activation
of this receptor initiates inflammatory signaling pathways similar to TLR activation, such as
the complement pathway (Dinarello, 2009). IL-1RII is termed a “decoy” receptor as binding
of IL-1 to the type II receptor does not mediate any physiological effects. The type II
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receptor is expressed ubiquitously on cells as well as being soluble. IL-1RII serves as
another way of tightly regulating IL-1 signaling (Dinarello, 1996).
Via NFκB and/or MAP kinase pathways, activation of TLR4 through LPS can induce IL-1β
gene transcription (Kim et al., 2004; Simi et al., 2002). Other documented stimuli for IL-1β
production in the brain are β-amyloid, hypoxia, ischemia, and seizures (Simi et al., 2007).
Unlike other secreted cytokines, IL-1β does not contain a leading/signaling sequence for
endoplasmic reticulum/golgi complex processing. Therefore, IL-1β is not likely to be
secreted through lysosomes like other common secreted cytokines (Andrei et al., 1999;
March et al., 1985; Singer et al., 1988) . Instead, IL-1β is first transcribed as a 31 kDA
immature form termed pro-IL-1β. This immature form is unstable and has no biological
activity (Beuscher et al., 1990; March et al., 1985). The biologically active, mature form (13
kDA), has to be cleaved from pro-IL-1β. This process as detailed in (Fig. 1.2), can be
catalyzed by the NALP3 inflammasome (Martinon et al., 2002). The inflammasome is a
multi-protein complex consisting of various adaptor proteins. In the CNS, an inflammasome
initiating event can be the activation of purinergic receptors, including the P2X7 receptor in
microglia. Activation of this receptor via ATP leads to K+ efflux. Although unclear, the
decrease in potassium has been implicated in the assembly of the NALP3 inflammasome
(Brough et al., 2003; Perregaux and Gabel, 1994). This includes key proteins procaspase-1,
NALP3 (cryopyrin), and apoptosis-associated speck-like protein (ASC) (Agostini et al.,
2004). Via the caspase activating recruiting domain (CARD) on the ASC protein, the inactive
procaspase-1 is cleaved into its mature, active form, caspase-1 (Mariathasan et al., 2006;
Srinivasula et al., 2002). This enzyme, a cysteine protease, can then cleave pro- IL-1β
between its Asp 116 and Ala 117 yielding mature IL-1β (Howard et al., 1991; Sleath et al.,
1990).
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Figure 1.2 The NALP3 inflammasome processes IL-1β utilizing the ATP receptor P2X7

The key molecular signal for the NALP3 inflammasome is extracellular ATP to activate
P2X7 receptors (Solle et al., 2001). ATP can act as an inflammatory mediator and many cell
types have purinergic receptors that are activated by ATP. The matter of which cell types
express the P2X7 receptor in the brain is controversial. Studies have cited that neurons,
microglia and astrocytes express them (Lee et al., 2008; Surprenant et al., 1996), while others
have indicated microglia are the only cell type to express the P2X7 receptor (Sim et al.,
2004).

In microglia, activation of the P2X7 receptor plays a critical role in NALP3

inflammasome activation and ultimately mature IL-1β production (Solle et al., 2001).
Sources of extracellular ATP in the brain include neurons, astrocytes, microglia, and
endothelial cells. In many cases, elevated ATP release from these cells occurs during CNS
inflammation. Neurons can release ATP in synapses (Gonzalez-Sistal et al., 2007; Sperlagh
et al., 1998a; Sperlagh et al., 1998b), while ATP is also released as a consequence of
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neuronal damage (Xia et al., 2012). Astrocytes also have been documented to release
extracellular ATP, especially during propagated calcium waves (Coco et al., 2003; Cotrina et
al., 1998; Guan et al., 1997). ATP can also be released by endothelial cells during
inflammation (Bodin and Burnstock, 1998).
In terms of how IL-1β is released from the cell, it is still not definitively determined. Various
hypotheses include the following: cell lysis (Le Feuvre et al., 2002), lysosomes (Andrei et al.,
1999; Andrei et al., 2004), microvesicle shedding (Bianco et al., 2005b; MacKenzie et al.,
2001), and direct passing through the cell membrane (Brough and Rothwell, 2007; Singer et
al., 1995). Nevertheless, given that the expression and secretion of IL-1β by microglia
increases significantly following activation, I will use the expression level of IL-1β as a
major index of microglia activation.

1.1.3.2

Cyclooxygenase-2

Cyclooxygenase (COX) is the enzyme that catalyzes the rate limiting step in the production
of prostaglandins. There are two isoforms, COX-1 and COX-2, which are 60% homologous
(Smith et al., 2000). Expressed in most tissues, COX-1 is constitutively active and produces
prostaglandins involved in maintaining homeostasis (Kraemer et al., 1992). The COX-2 gene
is also constitutively active in the central nervous system but can be induced by nuclear NFκB and cyclic AMP response element binding protein (CREB) (Appleby et al., 1994). Both
of these molecules are inflammatory signaling molecules that become activated in response
to inflammatory stimuli such as growth factors, LPS and inflammatory cytokines
(Akarasereenont et al., 1995; Flynn and Hoff, 1995). COX-2 is readily expressed in immune
cells such as microglia as well as neurons, glia, and endothelial cells (Bauer et al., 1997;
Hirst et al., 1999; Pasinetti and Aisen, 1998).

11

Prostaglandins are small, lipophilic eicosanoids that have various functions including
mediating inflammation (Funk, 2001). The primary step in prostaglandin synthesis is the
breakdown of membrane lipids by phospholipase A2 into arachidonic acid (AA). Regulated
by NF-κB, COX has two functional steps that generate prostaglandin precursors. The first is
the cyclooxygenase step in which COX converts AA into prostaglandin G 2 (PGG2) and then
the perioxidase activity of COX converts PGG2 into prostaglandin H2 (PGH2). This last step
also produces free radicals. PGH2 can be modified further by tissue specific prostaglandin
synthases to various prostaglandins (Consilvio et al., 2004).

1.1.3.3

Inducible nitric oxide synthase

Nitric oxide is an important intercellular signaling molecule that underlies several
physiological processes. As a free radical, NO can act as an inflammatory mediator that is
produced by immune cells.

There are three NO synthases, vascular endothelial NOS

(eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS). In macrophages and microglia,
iNOS is highly inducible in response to inflammatory stimuli such as LPS and cytokines
(Bal-Price and Brown, 2001). In the brain, iNOS is expressed in astrocytes and microglia,
where they produce and release NO upon activation (Brown et al., 1995; Chao et al., 1992).

1.1.3.4

Monocyte chemoattractant-1

Monocyte chemoattractant-1 or chemokine (C-C motif) ligand 2 (MCP-1/CCL2), is a
member of the β-chemokine subfamily. MCP-1 regulates the migration of inflammatory
cells such as microglia and lymphocytes to the site of inflammation (Babcock et al., 2003;
Zhou et al., 2007). This chemokine acts on the MCP-1 receptor (CCR2), which is expressed
by many cells including endothelial cells. Activation of the MCP-1 receptor in endothelial
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cells results in upregulation of certain adhesion molecules (e.g. ICAM-1) that are involved in
recruitment of immune cells such as microglia.
In the brain, MCP-1 secretion is mostly from astrocytes and microglia (Hayashi et al., 1995;
Zhou et al., 2007), although it has been reported that neurons also release MCP-1 as a
mechanism to recruit microglia (Hayashi et al., 1995; Yang et al., 2011). MCP-1 production
and secretion by microglia is dependent on NF-κB activation and microglia use MCP-1 to
migrate to the site of inflammation (Deng et al., 2009).

1.2 GABA signaling in the regulation of inflammation
GABA is synthesized in a highly regulated metabolic pathway (Martin and Rimvall, 1993).
Specifically, it is synthesized from glutamate via the enzyme glutamic acid decarboxylase
(GAD), which uses pyridoxal 5’-phosphate as a cofactor. GABA is used as a signaling
molecule or as an energy source (Martin and Rimvall, 1993). In neurons, GABA is packaged
in vesicles that are readily released by GABAergic neurons following depolarization in a
calcium dependent manner (Farrant and Nusser, 2005). The secreted GABA then diffuses
across the synaptic cleft and activates GABA receptors on the postsynaptic neuron. It has
been estimated that 20 – 50% of all neuronal synapses in the CNS utilize GABA as a
neurotransmitter (Bloom and Iversen, 1971; Young and Chu, 1990). Extracellular GABA is
rapidly cleared from the synaptic cleft by GABAergic neurons and surrounding glia, via the
activity of GABA transporters (Liu et al., 1993; Roettger and Amara, 1999), while some may
diffuse away from the synaptic cleft. GABA concentrations in presynaptic GABAergic
terminals range from 50 – 100 mM (Petroff, 2002) while the concentration of GABA in the
extracellular space can reach as low as 160 nM (Santhakumar et al., 2006). GABA acts on
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two types of receptors: GABAA, and GABAB receptors. GABAA receptors are ligand-gated
anionic channels while GABAB receptors are metabotropic (G-protein coupled) receptors.
My thesis study will mainly focus on the role of GABAA receptors in the regulation of
microglial activity.

1.2.1 GABAA receptor signaling in neurons
GABAA receptors are heteropentamers; i.e. a functional GABAA receptor consists of 5
subunits. There are 19 GABAA receptor subunits: α1-6, β1-3, γ1-3, δ, ε, θ, π and ρ1-3.
Different subunit compositions confer different pharmacological and physiological properties
of the GABAA receptor (Sieghart, 1995). In neurons, the majority of GABAA receptors
consist of two α subtypes, two β subtypes, and one γ subtype (McKernan and Whiting, 1996;
Sieghart et al., 1999). As members of the ligand gated ion channel superfamily, GABAA
receptor subunits share molecular structures similar to that of glycine and nicotinic
acetylcholine receptor subunits. Specifically, one subunit has four transmembrane domains,
with a large amino terminus domain located extracellularly that can bind GABA and other
modulators (Moss and Smart, 2001). GABAA receptors are pharmacologically important as
they recognize drugs such as benzodiazepines, barbiturates, steroids, and convulsants
(Sieghart, 1995, 2000). As ligand-gated anionic channels, GABAA receptors open and allow
mainly chloride (Cl-) ions to pass through its pore upon binding with GABA. In mature CNS
neurons, the opening of GABAA receptors usually leads to an influx of Cl-, resulting in a
hyperpolarization (inhibition) of the membrane potential.
In mature neurons, GABAA receptors mediate two types of inhibition (or two-types of
anionic currents): phasic and tonic inhibition. Phasic inhibition is characterized by a quick
onset, short lasting and large amplitude current. This is mediated by postsynaptic GABA A
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receptors in response to large-quantity vesicular release of GABA from GABAergic synaptic
terminals. Tonic inhibition, on the other hand, is characterized by persistent low-amplitude
current, which is due to constitutive activation of extrasynaptic GABAA receptors by ambient
extracellular GABA. These extrasynaptic receptors have a high sensitivity to GABA,
allowing them to respond to relatively low concentrations (~100 nM) of GABA in the
extracellular space (Farrant and Nusser, 2005; Santhakumar et al., 2006). Sources of ambient
GABA include spill-over GABA from synaptic release (Mitchell and Silver, 2000;
Semyanov et al., 2003), and non-synaptic release of GABA from astrocytes (Semyanov et al.,
2004)(also see below). The high sensitivity of extrasynaptic GABA A receptors to GABA
largely depends on subunit composition, specifically receptors that contain the α5 or δ
subunits (Caraiscos et al., 2004).

1.2.2 GABA signaling in astrocytes
Astrocytes, the major type of glial cells in the brain (Liu et al., 2011), play an essential role in
neuron signalling, survival and development (Ridet et al., 1997). Not only do they provide
metabolic support for neurons, but they are also involved in the uptake and clearance of
released neurotransmitters (Liu et al., 1993; Roettger and Amara, 1999). Moreover,
astrocytes have been described to be GABAergic – that is, they have the cell machinery to
produce and release GABA utilizing glutamic acid decarboxylase (Lee et al., 2011). As
mentioned above, astrocytes have been implicated as a source for GABA in the extracellular
space that is responsible for tonic activation of GABAA receptors (Lee et al., 2010). However
astrocytes release GABA via a non-vesicular mechanism. It is reported that in astrocytes
GABA is constitutively released into the extracellular space through bestrophin-1 (Best-1)
channels independent of neuronal activity and extracellular calcium. Bestrophin-1 channels
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are capable of passing GABA through its pore (Lee et al., 2010). Other mechanisms of
release of GABA from astrocytes have been proposed such as reversed transport, stretch
activated ion channels and P2X7 receptor-mediated release (Kimelberg et al., 1990;
Volknandt, 2002; Wang et al., 2002).
Astrocytes are also GABA receptive. Activation of GABAA receptors leads to depolarization
of the membrane potential (Kettenmann et al., 1984; Serrano et al., 2006) because of an
inherently high intracellular Cl- concentration. This leads to the extrusion of these anions
when the GABAA receptor gated channels open (Kimelberg et al., 1990). As a result of
depolarization, intracellular calcium concentration increases and results in astrocyte
activation (Bernstein et al., 1996; Fraser et al., 1995; Meier et al., 2008). Elevated
intracellular calcium leads to the initiation of various signalling pathways, including the
propagation of a calcium wave across astrocytes. Astrocytic release of ATP has been
implicated in the propagation of calcium waves as adding antagonists to P 2-purinergic
receptors blocked this propagation (Guan et al., 1997; Zanotti and Charles, 1997). Activation
of astrocytes has broad implications on the activity of other cells in the CNS including
regulating neuronal and microglial function (Liu et al., 2011; Perea et al., 2009).
Interestingly, astrocyte progenitor proliferation in the postnatal brain has been found to be
modulated by their GABAA receptors. These receptors are tonically activated by nonsynaptic
release of GABA from neuroblasts in the subventricular zone (Liu et al., 2005). Moreover,
activated astrocytes dynamically regulate the activity and function of microglial cells (see
below).
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1.2.3 Regulation of microglia activity by GABA signaling
Microglia express various neurotransmitter receptors that have been documented to modulate
their function. These include purinergic (Bianco et al., 2005a; Xiang and Burnstock, 2005),
glutamate (Hagino et al., 2004; Noda et al., 2000), cholinergic (De Simone et al., 2005;
Shytle et al., 2004) dopamine (Farber et al., 2005), adrenergic (Prinz et al., 2001) and GABA
receptors (Kuhn et al., 2004; Lee et al., 2011).
Activation of microglial GABAB receptors exhibit an outward K+ current (membrane
hyperpolarization) and a transient increase in intracellular calcium (likely through the
calcium-release activated calcium channel). In addition, GABAB receptor activation in LPSstimulated microglia results in a decrease of the release of proinflammatory cytokines IL-6
and IL-12p40 (Kuhn et al., 2004). On the other hand, the presence of functional GABA A
receptor-mediated signalling in microglia remains controversial. One recent study has shown
that adult human microglia express GABAA receptors and express the mRNA of the α1, α3
and β1 subunits (Lee et al., 2011). Furthermore, the authors indicated that stimulation of
GABAA receptors in activated microglia lead to the attenuation of increases in inflammatory
intracellular signalling mediators NF-κB and p38 MAP kinase. This resulted in a decrease in
the secretion of proinflammatory cytokines TNF-α and IL-6(Lee et al., 2011). However,
several studies have reported that stimulating microglia with GABA or GABAA receptor
agonists does not lead to any measurable current (Cheung et al., 2009; Wu and Zhuo, 2008)
or change in process motility (Chen et al., 2010).
Nevertheless, an increasing amount of evidence indicates that GABAA receptor-mediated
signaling in the brain can indirectly affect microglia activity. For example, the GABAA
receptor agonist muscimol has been shown to induce a transient increase in the conductance
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of K+ channels in microglia located on the surface of a mouse brain slice. This resulted in the
release of an inflammatory cytokine, macrophage inflammatory protein-1α (MIP-1α).
However, microglial GABAA receptors were not responsible for this effect as isolated
microglial cells did not respond to muscimol when removed from the brain slice. (Cheung et
al., 2009). In addition, retinal microglial morphology has also been shown to be modulated
by neurotransmission. Process motility was increased in response to ionotropic glutamatergic
neurotransmission but decreased in response to ionotropic GABAergic neurotransmission.
Furthermore, these effects were not directly mediated as direct application of GABA did not
affect microglia process motility. Instead, ATP seemed to be a downstream modulator that is
released in response to neurotransmission, and enables microglial activation (Fontainhas et
al., 2011). ATP has been indicated to play a critical role in microglial activation, especially
in the production and secretion of the proinflammatory cytokine interleukin 1-β (Clark et al.,
2010; Inoue, 2006). These findings indicate that the activation of GABAA receptors in other
cell types can indirectly regulate microglia activity.

1.2.4 GABA signaling in peripheral cells
Not only does GABA have an important role in neuronal signaling, but a growing amount of
evidence supports GABAA receptor signaling outside the CNS. Specifically, GABAA
receptors have been documented in peripheral tissues such as the pancreas, adrenal, ovary,
testis, small intestine (Akinci and Schofield, 1999), lung (Jin et al., 2005) as well as in
immune cells including T-lymphocytes (Tian et al., 1999) and macrophages (Reyes-Garcia et
al., 2007). A recurring theme in these studies indicates that GABA A receptors have an antiinflammatory effect. For example, GABAA receptors are expressed on islet β-cells and
activation of these receptors depolarizes the membrane potential. This leads to an increase in
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insulin secretion (Dong et al., 2006) and the promotion of β-cell survival (Soltani et al.,
2011). In the lung, GABAA receptors are expressed in pulmonary epithelial cells on the
airway apical membrane (Xiang et al., 2007). In addition, ongoing studies in our lab show
that the α5GABAA receptor is expressed in the type II epithelial cell, and these receptors may
play an essential role in pulmonary innate immunity (laboratory communication).
GABAA receptors have also been shown to modulate immune cell function. Studies have
shown that GABAA receptors are expressed in neutrophils, lymphocytes, and macrophages
(Nigam et al., 2010). For example, a study showed that T-lymphocytes express GABAA
receptors that resemble extrasynaptic receptors contained in neurons. These receptors were
activated at low concentrations of GABA (100 nM) and contained the α1,4, β2,3, γ1 and δ
subunits (Bjurstom et al., 2008). Activation of GABAA receptor in human T-lymphocytes
inhibits proliferation (Dionisio et al., 2011). In addition, activation of GABAA receptors on
peritoneal macrophages leads to reduced production of cytokines IL-6 and IL-12 in vitro
(Reyes-Garcia et al., 2007). Gabapentin, a GABA analogue, inhibits platelet aggregation
(Pan et al., 2007). Moreover, oral administration of GABA reduced antigen presenting cell
(APC) function and T cell activation and proliferation in a mouse model of rheumatoid
arthritis (Tian et al., 2011). Together these available data imply that GABA signalling is
fundamentally associated with negatively regulating innate and adaptive immunity of the
body.

1.2.5 GABAA receptors that contain the α5 subunit
In the mammalian brain, α5GABAA receptors are predominantly expressed in the
hippocampus (Sur et al., 1999). Located in the dendritic fields of the hippocampus,
α5GABAA receptors make up ~20% of all GABAA receptors in the hippocampus (Sur et al.,
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1999; Sur et al., 1998). The α5 subunit is also expressed in other parts of the brain such as the
olfactory bulb while its presence is low in the cerebral cortex and not expressed in most other
parts of the brain (Fritschy and Mohler, 1995; Gao and Fritschy, 1995; Sur et al., 1999). In
the entire brain, α5GABAA receptors make up less than 5% of all GABAA receptors (Sur et
al., 1999). Specifically, α5GABAA receptors are expressed extrasynaptically in pyramidal
neurons in the CA1 and CA3 regions and generate a tonic inhibitory conductance (Caraiscos
et al., 2004).

This tonic conductance occurs because α5GABAA receptors have two

properties that are important for tonic signaling. First, α5GABAA receptors have a relatively
high affinity for GABA compared to other subtypes and therefore α5GABAA receptors are
able to be activated at low, ambient concentrations of GABA (~100 nM) in the extracellular
space (Caraiscos et al., 2004; Santhakumar et al., 2006). It has been documented that
α5GABAA receptors containing the α5β3 subunits have 2-fold higher sensitivity to GABA
compared to GABAA receptors consisting of the subunits α1β2, thought to be the most
common GABAA receptor located in brain synapses (Caraiscos et al., 2004; McKernan and
Whiting, 1996). Secondly,

α5GABAA receptors desensitize more slowly than synaptic

receptors, therefore the conductance is persistent and long lasting, known as tonic
conductance (Yeung et al., 2003). α5GABAA receptors regulate the intrinsic excitability of
pyramidal neurons in the hippocampus as activation of these receptors result in
hyperpolarization (Bonin et al., 2007; Brickley et al., 1996; Hamann et al., 2002). The roles
of α5GABAA receptors in the regulation of brain functions have been studied extensively
using genetic knockout of the α5 subunit (Gabra5-/-) or pharmacological inhibition such as
utilizing the selective α5GABAA receptor inverse agonist L655,708. Among others, several
important studies have shown that Gabra5-/- mice have “improved” hippocampus dependent
spatial learning (Collinson et al., 2002), likely due to altered synaptic plasticity (Martin et al.,
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2010). Notably, a recent study has indicated that α5GABAA receptor activity increases during
systemic inflammation, and such an alteration is important for inflammation-induced
memory deficits (Wang et al., 2012).

1.3 Rationale and Hypothesis
1.3.1 Rationale
An accumulating amount of evidence has implicated an immunomodulatory role for GABA A
receptor mediated signaling in immune cells such as macrophages and microglia (Lee et al.,
2011; Reyes-Garcia et al., 2007). Microglia critically regulate inflammation in the brain
where they are activated by various stimuli. The activity and function of microglia are also
tightly regulated by neurotransmitters. Since microglia are not subject to GABAergic
innervations, I propose that microglial activity is regulated, directly or indirectly, by ambient
GABA in the extracellular space through the high affinity, constitutively active α5GABAA
receptor.

In this regard, a recent study indicates that α5GABA A receptor activity is

associated with brain inflammation (Wang et al., 2012). However, the mechanism by which
α5GABAA receptors regulate the innate immunity of the CNS and the process of
neuroinflammation remains largely unclear. This thesis investigates the role of α5GABAA
receptors in the regulation of microglial activation, as well as the related cellular and
molecular mechanisms. To this end, I proposed 1) to investigate the effect of intraperitoneal
LPS on the expression level of IL-1β in microglia of Gabra5-/- mice, in comparison with their
wild type littermates; and 2) to study how selectively blocking the α5GABAA receptor affects
the expression and secretion of IL-1β by cultured primary microglia primed with LPS.
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1.3.2 Hypothesis
On the basis of available knowledge, I hypothesize that interrupting α5GABA A receptor
signaling intensifies the LPS-induced microglia activation and the expression of IL-1β in
microglia.
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2

Chapter 2: Materials and Methods

To study the role of α5GABAA receptors in the regulation of microglial responses to
systemic inflammatory challenges, I examined the expression levels of CD11b and IL-1β in
the microglia of mice that lack the α5-subunit of GABAA receptor (Gabra5-/-) and their wild
type (WT) littermates. The Gabra5-/- mice were generated from the C57/BL6 mouse strain
(Collinson et al., 2002). To further elucidate possible molecular mechanisms by which
α5GABAA receptor regulates microglia activity, I prepared various cultures of primary brain
cells and tested the effects of an inverse agonist selective for α5GABA A receptors
(L655,708). Microglial activation was examined primarily through microglial morphology
and IL-1β expression/secretion, by means of immunochemistry and enzyme-linked
immunosorbent assays (ELISA).

2.1 Gabra5-/- mice
In collaboration with Dr. Beverley Orser in the Department of Physiology at the University
of Toronto, Gabra5-/- mice (Collinson et al., 2002) and their WT littermates were housed in
the University of Toronto animal care facility. The in vivo experiments in Gabra5-/- mice
were approved by the University of Toronto Animal Use Committee, in line with the
regulations of Canadian Council on Animal Care.
Male Gabra5-/- mice and their WT littermates aged 7–8 weeks and weighing 22–25 g were
divided into four groups (n = 4 in each group): WT control, WT-LPS, Gabra5-/- control, and
Gabra5-/--LPS. Male mice were purposely chosen to avoid the reported effect of the female
hormonal cycle on GABAARs subunit expression (Maguire et al., 2005).
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Mice in WT control and Gabra5-/- control groups were injected intraperitoneally (i.p.) with
0.2 ml phosphate-buffered saline (PBS), while mice in WT-LPS and Gabra5-/--LPS groups
were injected i.p. with LPS (serotype 026:B6, Sigma, 4.0 mg/kg in 0.2 ml PBS). Six hours
after LPS administration, mice were perfused transcardiacally with 20-25 ml PBS and then
with 10 mL 4% paraformaldehyde (PFA). Mouse brains were fixed in 4% PFA for 24 hours
and then stored in 30% sucrose solution at 4°C for 2-5 days. Brains were glued on a metal
block and coronal sections (40 μm thick) were cut using a vibratome (PELCO). Brain slices
were stored in cryoprotectant solution at -20°C until further use for immunohistochemistry.
To ensure consistent experimental conditions, a mouse brain from each group was sectioned
at the same day and stored in cryoprotectant. Brain sections cut from the same day were used
for immunohistochemistry analysis at the same time. Sections containing the same plane of
the hippocampus were used for immunohistochemistry.

2.2 Cell cultures
2.2.1 Primary rat hippocampal co-cultures
Cell culture: Primary mixed neuronal-glial cultures were prepared from the hippocampi of
embryonic day 18 (E18) rats, following a previously described protocol (Dinkel et al., 2004).
Briefly, pregnant (18 days) Sprague-Dawley rats were euthanized by cervical dislocation
under isoflurane anesthesia. Embryonic brains were removed and placed in ice-cold
dissection buffer containing Hanks balanced salt solution – Ca2+/Mg2+ free (Life
Technologies), 15 mM HEPES (Sigma), 0.5% glucose (Sigma), 2% sucrose (Sigma), 1 mM
sodium pyruvate (Sigma). Fetal hippocampi were isolated from each embryo and cells were
dissociated using mechanical trituration. Single cell suspensions were plated on poly-d-lysine
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(MW 70,000-150,000; P 6407, Sigma) coated 18-mm–diameter round glass cover slips
(Deckglaser) in 12-well plates (Nunc), at a density of 1 x 106 cells/well. Cultures were
maintained in a humidified atmosphere of 5% CO2 and 95% air in minimum essential
medium (MEM; 10370-021, Life Technologies) supplemented with 10% heat-inactivated
fetal bovine serum (FBS; Life Technologies), 10% heat-inactivated horse serum (HS; Life
Technologies), 1.0 g/L glucose (Sigma), 1 mM sodium pyruvate (Life Technologies), and 50
U/mL penicillin, and 50 μg/mL streptomycin, and 2 mM L-glutamine (PSG) (Life
Technologies).
Cell Treatment: Cells on the fifth day in culture were switched to serum-free MEM
supplemented with 1 mM sodium pyruvate and PSG. To determine the role of α5GABA A
receptor on microglia activity, the α5GABAA receptor inverse agonist L655,708 (1327,
Tocris), dissolved in dimethyl sulfoxide (DMSO; D5879, Sigma), was added to the culture
media at concentrations of 0.5 and 5.0 μM. It is reported that L655,708 has an affinity for the
GABAA receptor containing the α5 subunit 50-fold greater than GABAA receptors containing
other α subunits (Quirk et al., 1996). Experimental concentrations of L655,708 (0.5 and 5.0
μM) was used consistent with previous studies (Glykys et al., 2008; Khom et al., 2006;
Numata et al., 2012; Wang et al., 2012). Twenty-four hours after L655,708 pre-treatment, the
cultured cells were treated with both L655,708 and LPS serotype 026:B6 (L2654, Sigma, 50
ng/mL) for another 24 hours. The control cells were subject to the same concentration of
DMSO used in L655,708 treatment. To confirm the role of GABAA receptors in microglial
activation, the GABAA receptor antagonist bicuculline (Tocris; 50 μM) was added to the
culture media in combination with LPS.

25

As α5GABAA receptors inhibit the intrinsic excitability of neurons, I explored whether
neuronal activity affects the L655,708 induced IL-1β expression. Neuronal-glial cultures
were pre-treated for 24 hours with tetrodotoxin (TTX), which blocks voltage-gated, Na+
channels. L655,708 was then treated 24 hours after TTX pretreatment. The media from the
control and treated cells were collected and centrifuged at 3000 rpm for 5 minutes. The
supernatant was collected and aliquots were stored at -80°C for future ELISA.

2.2.2 Primary rat microglia
Microglial culture: Primary microglia were prepared from cortices of E18 Sprague-Dawley
rats as previously described (Liu et al., 2001). Briefly, isolated cortical neuronal-glial cells
were first cultured in 80 cm2 flasks (Nunc) maintained in a humidified atmosphere of 5%
CO2 and 95% air in DMEM supplemented with 10% FBS and PSG.

Upon reaching

confluency (10–14 days), microglia were separated from astrocytes by shaking flasks on a
benchtop shaking incubator (VWR) at 200 rpm, for 4 hours at 37°C. Suspended microglia in
the media were centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant was discarded
and single cell suspensions were plated on poly-d-lysine (MW 70,000–150,000; P 6407,
Sigma) coated 18-mm–diameter round glass cover slips in 12-well plates, at a density of 2.5
x 105 cells/well. Microglial cultures were maintained in a humidified atmosphere of 5% CO 2
and 95% air in DMEM supplemented with 10% FBS and PSG.
Microglial treatment: Twenty-four hours after plating, microglial cultures were switched to
serum free MEM supplemented with 1 mM sodium pyruvate and PSG. Microglial cultures
were treated the following day with LPS and L655,708 using the same procedure as the
neuronal-glial co-cultures. The media of microglial cultures were collected and centrifuged at
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3000 rpm for 5 minutes. The supernatant was collected and aliquots were stored at -80°C for
future ELISA.

2.2.3 Primary rat neurons
Neuronal culture: Following a previously described protocol (Dong et al., 2004), suspension
of dissociated hippocampal cells obtained from E-18 rats were plated on poly-d-lysine (MW
30,000–70,000; P7280, Sigma) coated 18-mm–diameter round glass cover slips in 12-well
plates, at a density of 1 x 105 cells/well. Cultures were initially plated in a humidified
atmosphere of 5% CO2 and 95% air. The plating medium consisted of Neurobasal medium
(Life Technologies) supplemented with 0.5 mM L-glutamine, 1x B-27 supplement (Life
Technologies), 0.5% FBS, 25 μM glutamic acid (Sigma), and 0.5 mM sodium pyruvate.
Two-thirds of the medium was replaced every two days with maintenance media which
consisted of Neurobasal medium supplemented with 0.5 mM L-glutamine and 1X B-27
supplement.
Neuronal treatment: Five days after plating, the neuronal cultures were switched to serum
free MEM supplemented with 1 mM sodium pyruvate and PSG. Neuronal cultures were
treated the following day with LPS and L655,708 using the same procedure as the neuronalglial co-cultures. The media from the cultured neurons were collected and centrifuged at
3000 rpm for 5 minutes. The supernatant was collected and aliquots were stored at -80°C for
future ELISA.

2.2.4 Primary rat astrocytes
Astrocytic cultures: Similar to the procedure used for primary microglial cultures, cell
suspensions of mixed neuronal-glial cells obtained from E18 rat cortices were plated on 100

27

mm culture dishes at a density of 1 x 105 cells/mL. Cells were incubated in a humidified
atmosphere of 5% CO2 and 95% air in DMEM supplemented with 10% FBS and PSG. Upon
reaching confluence, cells were split by trypsinization and re-seeded in 100 mm culture
dishes for the generation of a new passage. After three passages, cells were seeded on 18mm–diameter round glass cover slips in 12-well plates, at a density of 3 x 106 cells/well.
Astrocytic treatments: Upon reaching 80% confluence, astrocytic cultures were switched to
serum free MEM supplemented with 1 mM sodium pyruvate and PSG. Astrocytic cultures
were treated the following day with LPS and L655,708 using the same procedure as the
mixed neuronal-glial co-cultures. A438079 (100 μM), a P2X7 receptor antagonist was
pretreated for 24 hours and astrocytes were subsequently treated with both A438079 and LPS
for 24 hours. The media of the treated astrocytes were collected and centrifuged at 3000 rpm
for 5 minutes. The supernatant was collected and aliquots were stored at -80°C for future
ELISA.

2.2.5 Preparation of neuronal- and astrocytic-conditioned media
In the intact brain, microglia activity is subject to soluble factors from neurons and astrocytes
(Farber et al., 2005; Kuhn et al., 2004; Schilling et al., 2001). To study whether the
α5GABAA receptor regulates secreted soluble factors from these cells, primary microglial
cultures were treated with astrocytic or neuronal conditioned medium (ACM or NCM).
Specifically, primary astrocytes or neurons were treated using the same procedure as
mentioned above; cells were treated with the vehicle (control), LPS (50 ng/mL), LPS +
L655,708 (5 μM) or with LPS + A438079 (100 μM). After treatment, ACM or NCM were
collected and centrifuged at 1000 RPM for 5 minutes. The supernatant was then immediately
applied to primary microglia cultures. After 24 hours, the media were collected and
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centrifuged at 3000 rpm for 5 minutes. The supernatant was collected and aliquots were
stored at -80°C for ELISA.

2.3 Immunochemistry and confocal microscopy
Immunohistochemistry of brain sections: Brain sections of Gabra5-/- and WT mice were
washed three times with PBS and then permeablized with 0.25% Triton-PBS for 5 minutes.
Normal donkey serum (NDS; 10% in 0.25% Triton-PBS) was used to block sections for 2
hours at room temperature. Sections were then washed once for 5 minutes. Primary antibody
was applied in 2% NDS/0.25% Triton-PBS for 24 hours at room temperature. After three
washes, the secondary antibody was applied in 2% NDS/0.25% Triton-PBS for two hours at
room temperature. Double staining was achieved by applying another primary antibody and
subsequent secondary antibody. Sections were mounted between microscope slides and cover
slips with Fluoromount–G (#17984-25, Electron Microscopy Sciences). Images were taken
using a Zeiss confocal microscope (Carl Zeiss, Gottingen, Germany) primarily using a 40x
objective lens. Images were taken and saved in a computer via the LSM Image Browser
(LSM 510) for analysis.
Primary antibodies used in these studies included Rabbit Anti-Mouse IL-1β (1:200; 500-P51,
Peprotech) and Rat Anti-Mouse CD11b (1:150; MCA74G, AbD Serotec). Corresponding
secondary antibodies applied were Cy3-Donkey-Anti Rabbit immunoglobulin G (IgG)
(1:400; 70295, Jackson ImmunoResearch) and Fluorescein (FITC) Donkey-Anti Rat (1:200;
79415, Jackson ImmunoResearch).
Immunocytochemistry on primary cultures. After specific treatments as described above,
cultured cells were rinsed once with PBS and immediately fixed with 4% PFA for 10
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minutes. Cells on glass cover slips were then washed for 5 minutes with 0.1 M Glycine-PBS
and washed again with PBS 2 X 5 minutes. Cells were permeablized with 0.1% Triton-PBS
for 5 minutes and PBS washed 3 X 5 minutes. Blocking consisted of 1% NDS in PBS for 1
hour at room temperature. Primary antibodies were applied in 1% NDS solution overnight at
4 °C. After incubation, cells were washed 3 X 5 minutes in PBS and a corresponding
secondary antibody applied in 1% NDS. Negative controls consisted of applying secondary
antibodies only. For double staining, another primary antibody and subsequent secondary
antibody was applied. Finally, cells were mounted on a coverslip using Fluromount G. The
threshold of fluorescent detection was set to a level of ~1.5 times the fluorescent intensity of
the negative control. Electronic images of test tissues and cells were taken via the LSM 510
program.
Primary antibodies used in these studies included Rabbit Anti-Rat IL-1β (1:200; 500-P80,
Peprotech), Mouse Anti-Rat CD11b (1:150; MCA275FT, AbD Serotec), Mouse AntiNeuronal Nuclei (NeuN), clone 60, Alexa Fluor®488 conjugated (1:500; MAB377X,
Millipore), and Anti-Glial Fibrillary Acidic Protein (GFAP) Clone G-A-5 Cy3 Conjugate
(1:1000; C9205, Sigma). Corresponding secondary antibodies applied were Cy3-DonkeyAnti Rabbit IgG (1:400; 70295, Jackson ImmunoResearch) and FITC Donkey-Anti Mouse
(1:200; 75450, Jackson ImmunoResearch).
Image Analysis: All confocal microscopy images were analyzed by means of the java based
software ImageJ, provided by The National Institute of Health (NIH). For images taken from
hippocampal regions, special analyses were focused on the region just below the dentate
gyrus, because first, the α5-subunit is highly expressed in the hippocampus (Sur et al., 1999;
Sur et al., 1998) and that it is suggested that α5GABAA receptor expression increases in
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inflammation (Clarkson et al., 2010; Wang et al., 2012). Second, I observed a high density of
CD11b-positive microglia in this region. As illustrated in Figure 2.1, average intensities of
CD11b and IL-1β immunofluorescence were calculated by converting each image to
despeckled, black and white images. For each test mouse, a minimum of five images of the
hippocampus was analyzed.
For quantification of the immunofluorescent intensity of a test protein (e.g. IL-1β) in primary
cell cultures, the cell size and mean fluorescent intensity of single cells were measured (as
illustrated in Figure 2.2). In each experiment, a minimum of 70 cells per treatment were
analyzed. Specifically, the fluorescent intensities of test proteins were quantified and
averaged. The mean values of fluorescence measurements of each treatment group were
normalized to the mean measurement obtained from the control (non-treated) group.

Figure 2.1 Example image illustrating ImageJ analysis of IL-1β in hippocampal tissues.
Confocal images (left) are converted to black and white images (right) in ImageJ to calculate
expression intensity
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Figure 2.2 Example images illustrating ImageJ analysis of CD11b-immunofluorescence
in cultured microglia. Confocal images (left) are traced using ImageJ to calculate intensity
of CD11b expression and microglia cell size within the outlined area (right)

2.4 Phagocytosis assay
Phagocytosis is one of the primary functions of microglial cells. To examine the role of
α5GABAA receptors in the regulation of microglial phagocytosis, hipoocampi neuronal-glial
cell cultures were treated for twenty-four hours in the absence (control) or in the presence of
L655,708 (0.5 µM).

The phagocytotic ability of microglia was analyzed by using the

Phagocytosis Assay Kit following the manufacturer’s (Cayman Chemical Company)
instructions. In this assay, Latex Bead-Rabbit IgG-FITC Complex is added to cultures which
can be engulphed by microglia cells. FITC fluorescence in the microglia were taken by
confocal microscopy and the intensity of FITC fluorescence in the cells was analyzed using
ImageJ.
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2.5 ELISA
Media from co-cultures, primary neurons, astrocytes, and microglia were stored at -80°C
until they were used for ELISA. To measure secreted IL-1β levels in the media of primary
cultures, the rat IL-1β Quantikine ELISA kit (RLB00) was used according to the
manufacturer’s (R&D) instructions. In each individual experiment, samples were measured
in triplicate; three wells of cultured primary cells were treated with the same treatment and
IL-1β was measured from each of the three wells. Measurements were averaged and the
mean value would constitute a measurement for one treatment in one experiment.

2.6 Statistical analysis
Statistical analysis was conducted using the program GraphPad Prism 5 (San Diego,
California, USA). All data are presented as mean ± standard error of the mean (SEM) and
was examined using one way analysis of variance (ANOVA) followed by Tukey’s t-test.
Statistical significance was considered at the p < 0.05 level unless otherwise stated.
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3

Chapter 3: Results

3.1 Deletion of the GABAA receptor–α5 subunit increases the
microglial expression of IL-1β in mice challenged by
systemic administration of LPS
By immunohistochemical analysis of hippocampal sections of Gabra5-/- mice and their WT
littermates, I observed that under control conditions, CD11b-positive microglial cells in the
hippocampus (as well as other brain regions) displayed ramified processes. In addition, no
immunoreactivity of IL-1β was detected in hippocampal cells of Gabra5-/- mice and WT
mice. Moreover, in the region under the dentate gyrus and other regions of the hippocampus,
the immunofluorescent intensity of CD11b was significantly higher in the microglial cells of
control Gabra5-/- compared to their WT littermates (p < 0.01; Fig. 3.1B). Six hours after i.p.
administration of LPS, the immunoflouorescence of IL-1β was detected in few CD11bpositive microglial cells of WT mice. Notably, microglia in the hippocampus of Gabra5-/mice exhibited a significantly higher expression level of IL-1β compared to that of WT mice
(p < 0.01; Fig. 3.1C). I focused on the level of IL-1β in microglia as it is an important
proinflammatory cytokine that is critically involved in various inflammatory reactions (Simi
et al., 2007). The significant difference in the expression levels of both CD11b and IL-1β
between the Gabra5-/- and WT mice was noticeable only in hippocampal microglia. This
result implies that α5GABAA receptor mediated signaling is critically involved in the
regulation of microglial response to systemic inflammation.
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Figure 3.1 Higher expression of CD11b and IL-1β in microglia of Gabra5-/- mice
compared to WT mice (see previous page.) A) Representative images of CD11b and IL-1β
staining in the area under the dentate gyrus of the hippocampus in mice injected i.p. with
LPS. (See next page) B) Normalized immunofluorescent intensity of CD11b in the
hippocampus. Gabra5-/- (KO) mice displayed significantly higher expression in saline
injected (Ctrl) mice (* p < 0.01, n = 4). C) Normalized intensity of IL-1β in the
hippocampus.
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3.2 L655,708 increases microglial
neuronal-glial cultures

activation

in

mixed

Next I investigated the potential cellular and molecular mechanisms by which α5GABAA
receptor-mediated signaling regulates microglial activation in LPS-induced systemic
inflammation. To this aim, I treated mixed neuronal-glial co-cultures with LPS to evoke
immune reactions in brain cells, and used L655,708 to selectively block α5GABAA receptor
signaling. Mixed neuronal-glial cultures consisted primarily of neurons, astrocytes and
microglia. The effects of LPS and L655,708 were analyzed by examining the morphology of
microglial cells and the expression and secretion of IL-1β. I had the following findings.
First, CD11b-positive microglia in mixed neuronal-glial co-cultures exhibited an oval shape
with short ramified processes. In control cells, a basal level of IL-1β immunofluorescence
was observed in almost all CD11b-positve microglia (Fig. 3.2A). Treating the mixed cocultures with L655,708 (5 μM) significantly increased the expression levels (measured by
immunofluorescent intensity) of CD11b and IL-1β in microglia (Fig. 3.2; p < 0.01).
Second, selective blockade of α5GABAA receptor signaling [L655,708 (0.5 – 5 μM)]
increased the phagocytotic activity of microglia, displaying higher fluorescent intensity of
FITC in mixed neuronal-glial co-cultures in comparison to control cultures (Fig. 3.3; p <
0.01) .
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Figure 3.2 Microglia exhibit higher expression of CD11b and IL-1β in mixed
hippocampal co-cultures treated with α5GABAA receptor inverse agonist L655,708. (See
previous page) A) Representative images of co-cultures with CD11b and IL-1β. B)
Normalized CD11b-immunofluorescent intensity (* p < 0.01, n = 6 separate experiments). C)
Normalized IL-1β intensity (* p < 0.01, n = 6). D) The average size of microglia cells (* p <
0.01, n = 6).
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Figure 3.3 Microglia exhibit higher phagocytotic activity in mixed hippocampal cocultures treated with L655,708. A) Representative images of FITC-IgG in co-cultured cells
that were treated with L655,708 (5 μM) and without (control) L655,708. B) Normalized
FITC intensity. (* p < 0.01, in each group n = 6-8 images of cultured cells in 2 separate
experiments).
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Treating the co-cultures with LPS (50 ng/mL) also significantly increased the expression
levels of CD11b and IL-1β. Notably, when co-cultures were treated with both L655,708 (5
μM) and LPS (50 ng/mL), microglia exhibited significantly higher expression levels of
CD11b and IL-1β, in comparison to co-cultures treated with LPS alone (Fig. 3.4; p < 0.01).
Another important finding was that microglial morphology changed from a larger oval shape
with extended processes to a smaller round shape without processes when co-cultures were
treated with both L655,708 and LPS, in comparison to co-cultures that were treated with LPS
alone (Fig. 3.4A). This was evident by measuring the size of CD11b-positve microglia (Fig.
3.4D; p < 0.01). Such a change in microglial morphology may imply increased activation of
microglia.
Treating the mixed co-cultured cells with bicuculline (50 μM), a GABAA receptor antagonist,
mimicked the effect of L655,708, resulting in a higher expression of IL-1β in microglia.
Bicuculline also increased the LPS-induced IL-1β expression in microglia when applied
together with LPS (Fig. 3.5; p < 0.01;).
Finally, ELISA of the culture media from neuronal-glial cultures showed that treating the cocultures with LPS significantly increased the concentration of IL-1β in the culture medium,
although no IL-1β was detectable in the medium of control cells.

Surprisingly, the

concentration of secreted IL-1β from co-cultures treated with both LPS and L655, 708 (0.55.0 µM) was significantly lower than that of co-cultures treated with LPS alone (Fig. 3.6; p <
0.01). IL-1β was not detected from co-cultures treated with L655,708.
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Figure 3.4 Microglia in mixed hippocampal co-cultures treated with L655,708 and LPS
exhibit higher expression of CD11b and IL-1β compared to co-cultures treated with
LPS alone. (See previous page) A) Representative images of co-cultures treated with LPS
(50 ng/mL) and/or L655,708 (5 μM). B) Normalized CD11b-immunofluorescent intensity. (*
p < 0.01, n = 6 separate experiments) C) Normalized IL-1β-immunofluorescent intensity (* p
< 0.01, n = 6). D) Microglia cell size (* p < 0.01, n = 6).
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Figure 3.5 Blockade of GABAA receptors increases the expression of CD11b and IL-1β.
(See previous two pages) A-C) Microglia in mixed hippocampal co-cultures treated with
bicuculline exhibit higher expression of CD11b and IL-1β compared to control. A)
Normalized CD11b intensity. (* p < 0.01, n = 3 separate experiments) B) Normalized IL-1β
intensity (* p < 0.01, n = 3) C) Microglia cell size (n = 3) D-F) Co-cultures treated with both
bicuculline and LPS compared to co-cultures treated with LPS alone. D) Normalized CD11b
intensity (n = 3) E) Normalized IL-1β (* p < 0.01, n =3) F) Microglia cell size (n = 3)
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Figure 3.6 Treatment of LPS-primed hippocampal co-cultures with L655,708 decreases
the extracellular concentration of IL-1β. ELISA of IL-1β in the medium of co-cultures
treated without (Ctrl) or with LPS and/or LPS + L655,708. IL-1β concentrations in the
culture media: LPS (50 ng/mL) treatment = 66 ± 5 pg/mL; LPS + L655,708 (0.5 μM) = 37 ±
5 pg/mL; LPS + L655,708 (5.0 μM) = 30 ± 2 pg/mL; * p < 0.01, n = 3.
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Taken together, these in vitro results indicate that 1) consistent with the finding in Gabra5-/mice, interrupting α5GABAA receptor signaling increased the activity of microglial cells to
inflammatory stimulants such as the bacterial endotoxin LPS; and 2) these changes in
microglial activities are due to alterations in α5GABAA receptor mediated signaling among
brain cells, but not associated with peripheral cells.

3.3 α5GABAA receptors indirectly affect microglial IL-1β
expression through modulating astrocytes and neurons
In neuronal-glial cultures, the effects of L655,708 on microglial morphology and expression
of IL-1β could be due to its direct action on microglial cells and/or because of its indirect
action on neurons or astrocytes. Given the experiments performed by other members in my
laboratory showing that 1) GABA failed to evoke detectable current in primary rat microglia
or in mouse microglial line of BV2 cells; and 2) no mRNA of α5-subunit was detectable in
BV2 cells by polymerase chain reaction (PCR) assays (acknowledged by laboratory
communications), I tested whether α5GABAA receptors in neurons or astrocytes indirectly
regulate microglial activation through the following experiments.
First I tested the effects of L655,708 and LPS on the expression of IL-1β in isolated primary
microglia cultures. Immunocytochemical analyses showed that after described procedures of
microglia isolation, ~95% of cells in the cultures exhibited immunofluorescence for CD11b.
As shown in Fig. 3.7, these isolated CD11b-positive microglia displayed a ‘resting’, ramified
morphology – branched, extended processes from a small cell body. Interestingly, treating
isolated microglia with LPS (50 ng/mL) increased CD11b and IL-1β expressions only in a
few (less than 0.1%) cells. In addition, treating the microglia with L655,708 (5 µM) had no
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Figure 3.7 Treatment of isolated cortical microglia with L655,708 and/or LPS does not
significantly affect the expression level of CD11b and IL-1β. (See previous page) A)
Representative images of primary microglia treated with L655,708 (5 μM) and LPS (50
ng/mL). B) Normalized CD11b-immunofluorescent intensity in microglia (n = 2 separate
experiments) C) Normalized IL-1β intensity in microglia (n = 2) D) Microglia cell size (n
=2) E) ELISA did not detect IL-1β in the media of primary microglia cultures that were
treated without (Ctrl), or with L655,708, or with LPS.
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effect on the expression levels of CD11b and IL-1β (Fig. 3.7B-C). Moreover, IL-1β in the
medium of microglial cultures was not detectable (Fig. 3.7E). The absence of IL-1β
expression and secretion suggest that 1) LPS-induced microglial activation requires cofactor(s) from astrocytes or neurons; and 2) the α5GABAA receptor regulates microglial
activation possibly through modulating the activity of astrocytes or neurons.
I also determined the effects of L655,708 and LPS on CD11b and IL-1β expressions in
isolated primary neurons. Treating the cultured neurons with L655,708 (5 µM) and LPS (50
ng/mL) had no effect on the expression of CD11b and IL-1β (Fig. 3.8). IL-1β was not
detectable in the medium of isolated primary neurons treated with L655,708 or with LPS.
Next, the effects of L655,708 and LPS on the expression of IL-1β in isolated primary
astrocytes were examined. Immunocytochemical analysis showed that under my
experimental conditions, astrocyte cultures were ~98% pure, with ~2% of cells consisting of
microglia (Fig. 3.9). Treating the isolated astrocytes with LPS (50 ng/mL) increased the
immunofluorescent intensity of IL-1β in astrocytes, in comparison to control conditions.
However, L655,708 (5 µM) did not significantly affect the LPS-induced increase of IL-1β
expression (Fig. 3.9A). The concentration of IL-1β in the medium of astrocytes significantly
increased following LPS treatment. Remarkably, the LPS-induced increase of IL-1β in the
astrocytic media was significantly reduced by treating astrocyte cultures with L655,708 (Fig.
3.9B; p < 0.05). These results imply that α5GABAA receptors are expressed in primary
astrocytes and they down-regulate their response to inflammatory stimulants such as LPS.
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Figure 3.8 Treatment of isolated hippocampal neurons with L655,708 and/or LPS does
not affect the expression level of IL-1β. Representative images of immunofluorescence of
NeuN and IL-1β in hippocampal neurons treated with L655,708 (5 μM) and LPS (50 ng/mL).
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Figure 3.9 Treatment of isolated astrocytes with L655,708 and/or LPS increases IL-1β
expression. (See previous page) A) Representative images of isolated cortical astrocytes
treated with LPS (50 ng/mL) alone or with LPS+ L655,708 (5 μM). LPS treatment increased
the expression level of IL-1β in the astrocytes. L655,708 treatment also increased the IL-1β
immunofluorescent intensity in LPS-primed astrocytes. B) ELISA revealed a significant
decrease of IL-1β in the media of LPS-primed astrocyte cultures treated with L655,708. IL1β concentrations in the culture media: LPS (50 ng/mL) treatment = 260 pg/mL; LPS +
L655,708 (0.5 μM) = 178 pg/mL; LPS + L655,708 (5 μM) = 107 pg/mL; LPS + A438079
(100 μM) = 370; n = 2 separate experiments.
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As mentioned above, evidence indicates that microglia do not express α5GABA A receptors.
Therefore, it is likely that α5GABAA receptor mediated signaling through other cell types
may indirectly modulate microglial activity. To examine the possibility that α5GABAA
receptors regulate microglial activation through astrocytes or neurons, isolated microglia
were treated with astrocyte (ACM) or neuron (NCM) conditioned media. Conditioned media
was obtained by treating astrocytes and neurons with LPS alone or LPS with L655,708.
Microglial cultures were treated with CM for 24 hours, and microglial IL-1β expression and
secretion were analyzed by immunocytochemistry and ELISA, respectively.
Microglia exhibited different morphologies in response to CM (Fig. 3.10). Primary microglia
displayed a ramified morphology in control media and in non stimulated (control) NCM,
indicating that they were in a resting state. Microglia treated with control ACM exhibited
larger, oval cell bodies with retracted processes. This suggests that they were partially
activated. This result indicates that soluble factor(s) secreted from astrocytes regulates the
activity of microglia.
Treating

primary

microglia

with

LPS-primed

or

L655,708+LPS-primed

NCM,

immunofluorescent intensity of CD11b and IL-1β in microglia increased slightly in
comparison to the control (Fig. 3.11). IL-1β concentration was not detected in the media.
Treating isolated microglia with LPS-primed ACM significantly increased the CD11b and
IL-1β expression in microglia in comparison to control-ACM. In addition, microglia
expressed higher levels of CD11b and IL-1β in L655,708+LPS-primed ACM (Fig. 3.12A).
IL-1β concentration also increased in the media of microglia cultured in LPS-primed ACM,
while L655,708+LPS-primed ACM exhibited a trend of increasing IL-1β secretion further
(Fig. 3.12B).
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Figure 3.10 Microglia exhibited resting, ramified morphology in nonstimulated
conditions and control neuron conditioned media while microglia exhibit an activated
morphology when grown in control astrocyte conditioned media. Note that microglia
treated with neuronal-conditioned medium show a ramified morphology and lower
expression levels of CD11b and IL-1β, which are similar to that of microglia cultured in
control condition.
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Figure 3.11 Isolated primary microglia exhibit increased IL-1β expression when treated
with LPS+L655,708-neuronal conditioned media. Represenative image of microglia
treated with L655,708 (5 μM) and LPS (50 ng/mL) conditioned neuronal media.
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Figure 3.12 Isolated primary microglia exhibit increased IL-1β expression when treated
with LPS+L655,708-astrocyte conditioned media. (See previous page) A) Represenative
image of microglia treated with L655,708 (5 μM) and LPS (50 ng/mL) conditioned astrocyte
media. Microglia express higher CD11b and IL-1β intensity compared to control. B)
Secreted IL-1β was higher in microglia treated with L655,708+LPS ACM, relative to LPSprimed ACM. IL-1β concentrations in the culture media: LPS (50 ng/mL) treatment = 463
pg/mL; LPS + L655,708 (0.5 μM) = 664 pg/mL; LPS + L655,708 (5 μM) = 800 pg/mL;
LPS+A438079 (100 μM) = 907; n = 2.
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3.4 α5GABAA receptors regulate microglial IL-1β expression
possibly through P2X7 receptors
Tetrodotoxin (TTX) decreases neuronal network activities by blocking voltage-gated Na+channels and hence eliminating the generation of action potentials by neuronal cells. Treating
the mixed cell co-cultures with TTX (100 µM) did not lower the L655,708 induced increase
in the immunofluorescent intensities of CD11b and IL-1β in microglial cells (Fig. 3.13). This
data suggests that α5GABAA receptor regulates microglial activation unlikely through
regulating the activity of neuronal networks.
As the P2X7 receptor has been implicated in microglial processing of IL-1β, I used a specific
antagonist, A438079, to determine if this receptor played a role in IL-1β secretion. A438079
was used in astrocyte cultures as they too have been reported to release ATP and express
P2X7 receptors (Coco et al., 2003; Suadicani et al., 2006).

In LPS-primed astrocytes,

A438079 increased IL-1β secretion (Fig. 3.9B; p < 0.05). A438079 had a similar effect in
LPS-primed ACM, increasing IL-1β secretion from microglia compared to microglia treated
with just LPS-primed ACM (Fig. 3.12B). These data suggest that the P2X7 receptor-mediated
signaling in astrocytes and/or microglia modulate IL-1β release from both cell types.
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Figure 0.1 Microglia in mixed hippocampal co-cultures treated with L655,708 and
tetrodotoxin (TTX) exhibit similar expression of CD11b and IL-1β compared to cocultures treated with L655,708 alone. (See previous page) A) Representative images of cocultures treated with L655,708 (5 μM) and/or TTX (100 μM) B) Normalized CD11b
intensity. C) Normalized IL-1β intensity (* p < 0.01, n = 2). D) Microglia cell size (n = 2).
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Chapter 4: Discussion

My thesis study explored the role of α5GABAA receptors in the regulation of microglial
activation by in vivo and in vitro experiments. Three important findings arise from these
experiments. First, Gabra5-/- mice exhibit increased IL-1β expression in hippocampal
microglia in response to systemic inflammation. In addition, selective blockade of α5GABA A
receptor-mediated signaling in mixed neuronal-glial cultures elevated IL-1β expression in
microglia. Finally, the regulation of microglial IL-1β expression and secretion by α5GABAA
receptors was mediated indirectly by undetermined soluble factor(s) from neurons and/or
astrocytes. These findings established a critical role for α5GABAA receptor signaling in
microglial activation.

4.1 Interrupting α5GABAA
microglial activation

receptor

signaling

increases

Microglia, the resident macrophages of the brain, become “activated” in response to various
stimuli and undergo phenotypic and morphological changes to maintain brain homeostasis.
These changes include the up-regulation of the production and secretion of proinflammatory
cytokines and phagocytic capability. An accumulating amount of evidence indicates that
GABAA receptors regulate the functions of immune cells including peritoneal macrophages
and T-lymphocytes (Reyes-Garcia et al., 2007; Tian et al., 1999). Although a previous study
reported the expression of GABAA receptors in microglia (Lee et al., 2011), whether GABAA
receptors regulate microglial activities remains to be examined. Microglial cells lack synaptic
innervations because their cellular ultra-structures and their locations change dynamically
(Nimmerjahn et al., 2005). Thus I proposed that GABAA receptors in microglia should be
able to sense ambient GABA in the extracellular fluid of brain tissues. In this regard,
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previous studies have demonstrated that the α5GABAA receptor has a high affinity for
GABA and thus it is persistently activated by ambient, extracellular GABA (Caraiscos et al.,
2004). Importantly, α5GABAA receptors are critically involved in the process of brain
inflammation (Wang et al., 2012). Therefore, I specifically examined the possible role of
α5GABAA receptors in modulating microglial activity.
To address this issue I carried out immunohistochemistry of brain tissues from Gabra5-/mice and their WT littermates, which were challenged by intraperitoneal LPS. Specifically I
examined the expression levels of IL-1β in hippocampal microglia that were identified by the
immunostaining of CD11b. Intraperitoneal LPS has been widely used as a model of systemic
inflammation because it mimics the pathology of systemic bacterial infections. In addition,
LPS was used to directly activate microglia in vitro as they readily respond to LPS via
binding to TLR4 (Olson and Miller, 2004)
In my studies I examined the microglial expression of IL-1β, as it is one of the prototypical
proinflammatory cytokines produced by microglia and plays a pivotal role in brain
inflammation (Sims and Smith, 2010). CD11b expression reflects microglia acivity as
CD11b has been found to be upregulated in microglial activation. (Duan et al., 2006; Frank et
al., 2010; Le Cabec et al., 2002; Roy et al., 2006). As such, CD11b was stained as the
specific microglial marker in this study. Importantly, CD11b-immunofluorescence is
primarily associated with the cell membrane, sketching the morphology of microglia. My
analyses were focused in the hippocampus as α5GABAA receptors are predominantly
expressed in this brain region (Sur et al., 1999).
Immunohistochemical results showed that the expression level of CD11b was significantly
higher in hippocampal microglia of Gabra5-/- mice, relative to their WT littermates (Fig.
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3.1B). This implies that without induced inflammation, interrupting α5GABAA receptor
signaling alters microglial activity. As previously reported (Gabellec et al., 1995; Singh and
Jiang, 2004), my analyses revealed that intraperitoneal injection of LPS readily induced
inflammation in the brain of both Gabra5-/- mice and WT mice, displaying increased IL-1β
expression in hippocampal microglia 6 hours after LPS injection (Fig. 3.1A). The expression
level of IL-1β in hippocampal microglia of Gabra5-/- mice was significantly higher than that
in WT littermates (Fig. 3.1C). IL-1β positive cells in the hippocampus were also CD11b
positive, displaying ramified processes. This indicates that these are microglial cells and
likely not parenchymal infiltrated peripheral immune cells.

This difference was only

observed in the hippocampus and not in other brain regions such as the cortex. This finding
not only verifies that the down-regulation of α5GABAA receptor signaling increases
microglial activation in response to systemic inflammation, but also suggests that the
increased microglial activity in the hippocampus of Gabra5-/- mice is due to alterations in the
function of hippocampal cells.
My in vitro studies revealed that selectively blocking α5GABAA receptor signaling in mixed
neuronal-glial co-cultures with L655,708 increased the expression level of CD11b and IL-1β
significantly in microglial cells in the absence (Fig. 3.2) and presence of LPS (Fig. 3.4). The
general GABAA receptor antagonist bicuculline mimicked the effect of L655,708 (Fig. 3.5).
In addition, blocking α5GABAA receptors in LPS-primed co-cultures with L655,708 changed
the morphology of microglia from a larger, oval shape with processes to a rounder, smaller
morphology with retracted processes (Fig. 3.4A). This type of amoeboid morphology has
been documented to be one of the final stages of microglial activation, where microglia have
increased mobility and phagocytic ability (Lynch, 2009; Reichert and Rotshenker, 2003;
Stence et al., 2001). Indeed, the phagocytic assay showed that selectively blocking
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α5GABAA receptor signaling in the co-cultures significantly increased the phagocytotic
ability of microglia. Specifically treating the mixed neuronal-glial cultures with L655,708
largely increased the fluorescent intensity of IgG-FITC in microglial cells (Fig 3.3).
Phagocytosis is a hallmark of innate immune cells such as microglia, and the phagocytotic
ability of microglia increases upon activation (abd-el-Basset and Fedoroff, 1995; Lynch,
2009; Reichert and Rotshenker, 2003). Selective blockade of α5GABAA receptors elevated
microglial expression of IL-1β and CD11b and increased microglial phagocytyosis in
neuronal-glial co-cultures, which implies that the increased microglial activation in Gabra5-/mice is due to an alteration of α5GABAA receptor signaling among brain cells. The
combined results from my in vivo and in vitro studies establish that under “normal”
conditions, the tonic activity of α5GABAA receptors restrains the activity of microglia,
because down-regulating these receptors leads to the activation of microglia through
increased expression of IL-1β and CD11b. Furthermore, inhibiting the tonic activity of
α5GABAA receptors in LPS-primed neuronal-glial cultures increased activated microglia
further, exhibiting amoeboid-like morphology and increased expression of IL-1β and CD11b.
Interestingly, blocking α5GABAA receptors significantly suppressed the LPS-induced
increase of IL-1β in the media of mixed neuronal-glial co-cultures (Fig. 3.6). In the brain, IL1β is expressed and released by various cell types, including neurons (Lechan et al., 1990;
Watt and Hobbs, 2000) and astrocytes (Knerlich et al., 1999; Zhang et al., 2000). Thus IL-1β
in the media of LPS-treated neuronal-glial cultures could be secreted from multiple types of
brain cells in addition to microglia. Furthermore, α5GABAA receptors may modulate IL-1β
secretion from these cells as hippocampal neurons express these receptors (Caraiscos et al.,
2004; Collinson et al., 2002). It is undetermined whether astrocytes express the α5GABAA
receptor, but it is well documented that astrocytes contain GABAA receptors, which activate
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astrocytes (Lee et al., 2011; Lee et al., 2010). Therefore, it is possible that blocking
α5GABAA receptor signalling in neuronal-glial cultures by L655,708 increases IL-1β
secretion from microglia but decreases IL-1β secretion from other cell types. To explore the
possible cellular and molecular mechanisms by which α5GABAA receptors regulate
microglia activity, I decided to dissect the complex actions of GABAergic signaling in the
regulation of microglia, astrocytes and neurons under specific conditions. In particular, I
investigated the expression profile of IL-1β in microglial cells that were grown in
conditioned media from cultured neurons or astrocytes that were treated with or without LPS
and the α5GABAA receptor inverse agonist.

4.2 α5GABAA receptors regulate microglial activity: an indirect
action
GABAA receptors have been reported to be expressed in microglia (Lee et al., 2011),
although a GABAA receptor-mediated change in membrane potential or in transmembrane
current has never been demonstrated (Cheung et al., 2009; Wu and Zhuo, 2008).
Nevertheless, it is important for this study to define whether microglial cells express α5subunit of GABAA receptors. Reverse Transcriptase Polymerase chain reaction (RT-PCR)
analysis conducted in our lab indicates that the murine microglial cell line BV-2 do not
express the mRNA of the GABAA receptor α5-subunit. In addition, patch-clamp recordings
failed to detect transmembrane current in primary microglia and/or BV-2 microglia during
perfusion with the GABAA receptor agonist muscimol (by laboratory communications).
Indeed, my analyses showed that IL-1β expression (Fig. 3.7A) and secretion (Fig. 3.7E) in
isolated microglial cells remained unchanged in response to L655,708. However, it has been
reported that GABAergic transmission regulates microglial activity in an indirect manner
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(Cheung et al., 2009; Fontainhas et al., 2011). Unlike in neuronal-glial co-cultures, isolated
primary microglia remain in a resting status, displaying small cell bodies and long, branched
processes even in the presence of LPS and/or L655,708 (Fig. 3.7A). Collectively, available
data from the literature and my studies highly suggest that the increased microglial activation
in Gabra5-/- mice is not due to a direct alteration of GABAA receptor signalling in microglial
cells, but rather through indirectly modulating the secretion of soluble factors from other
brain cells which express α5GABAA receptors (e.g. neurons and/or astrocytes).

4.2.1 α5GABAA receptors regulate microglial activation likely through the
modulation of astrocyte activity
Astrocytes have also been reported to secrete proinflammatory cytokines in response to LPS
(Carpentier et al., 2008; Guerra et al., 2011). Indeed, my experiments confirmed that treating
isolated primary astrocytes with LPS greatly increased the IL-1β expression (Fig. 3.9A) and
secretion (Fig. 3.9B) in culture. As mentioned previously, astrocytic GABAA receptor
stimulation leads to elevated intracellular Ca2+ and subsequent astrocyte activation. This
activation leads to the release of various soluble factors such as ATP. However, whether
GABAA receptors in astrocytes contain α5-subunits remains elusive as it is difficult to purify
primary astrocytes for PCR assays and no specific α5-subunit antibody is available for
immunocytochemistry. Using the inverse agonist L655,708, I found that selective blockade
of α5GABAA receptor signalling in primary astrocytes suppressed the LPS-induced increase
in IL-1β secretion (Fig. 3.9B). This result implies that astrocytes are endowed with an
α5GABAA receptor-mediated autocrine signaling mechanism, which constantly stimulates
the cells to produce and secrete cytokines such as IL-1β during brain inflammation.
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Taking these results into account may help explain how L655,708 treatment in LPS-primed
neuronal-glial cultures decreased the IL-1β concentration in the media. That is, in neuronalglial cultures, both astrocytes and microglia respond to LPS by increased production and
secretion of IL-1β. Moreover, blockade of α5GABAA receptor-mediated excitation in
astrocytes largely decreased the astrocytic secretion of IL-1β, but still increased microglial
secretion of IL-1β possibly through an astrocytic soluble factor (see below).
To examine whether α5GABAA receptor indirectly regulates microglia activation via
astrocytic secreted soluble factor(s), I tested the effects of astrocyte conditioned media
(ACM) on the expression and secretion of IL-1β by isolated primary microglia. Specifically,
astrocytes were treated with LPS alone or with L655,708+LPS, and subsequent ACM (LPSprimed ACM, which contained LPS; or L655,708+LPS-primed ACM, which contained
L655,708+LPS) were used to treat primary microglia cultures, respectively. My assays
showed that the LPS-primed ACM induced a large amount of IL-1β secretion by the isolated
primary microglia (Fig. 3.12B). This result indicates that under my experimental conditions
microglial activation by LPS requires undetermined astrocytic soluble factor(s).
Remarkably, L655,708+LPS-primed ACM caused a higher extent of microglial secretion of
IL-1β compared to LPS-primed ACM (Fig. 3.12B). On the basis of my results, I propose that
the blockade of α5GABAA receptor mediated autocrine signaling in astrocytes inhibits
astrocytic excitation. This inhibition decreases the release of astrocytic soluble factor(s) such
as ATP (Davalos et al., 2005), which negatively control microglial production and secretion
of IL-1β (see below and illustration in Fig. 4.1). Another possible factor is S100B, a calcium
binding protein secreted from astrocytes in response to LPS (Guerra et al., 2011). As a
cytokine, S100B from astrocytes has been reported to increase IL-1β release from microglia
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in am NF-κB dependent manner (Bianchi et al., 2010). The proposed notion awaits further
experiments for validation.

A

B

Figure 4.1Proposed mechanism of α5GABAA receptors on microglial expression of IL1β. A) In LPS stimulated conditions, astrocytes secrete soluble factors necessary for the
production/secretion of IL-1β in microglia. B) α5GABAA receptors expressed on astrocytes
increase IL-1β secretion from astrocytes, however, they release other soluble factors such as
ATP that may inhibit microglial IL-1β.

4.2.2 α5GABAA receptor mediated signaling in neurons play a minor role
in regulating the production of IL-1β in the brain
The α5GABAA receptors generate a tonic conductance in hippocampal neurons and
interruption of this signaling leads to increased neuronal excitability (Bonin et al., 2007).
Therefore, I also examined whether blockade of α5GABAA receptors affects neuronal
production of IL-1β. Although it has been reported that neurons may secrete IL-1β (Watt and
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Hobbs, 2000), isolated hippocampal neurons did not secrete IL-1β in control conditions and
in the presence of LPS and/or L655,708 (Fig. 3.11B). Moreover, unlike ACM, the control
neuronal conditioned media (NCM), LPS-primed NCM and the L655,708+LPS-primed
NCM had minor effects on microglial IL-1β expression. That is, microglial cells cultured in
these NCM exhibited ramified morphologies and a low intracellular level of IL-1β (Fig. 3.
11A). Taking into consideration that treating the neuronal-glial co-cultures with tetrodotoxin
(TTX, an Na+ channel blocker that blocks neuronal network activity) did not affect the
L655,708-induced increase of IL-1β expression in microglia (Fig. 3.13), I conclude that
altered neuronal network activity via α5GABAA receptors did not play a major role on
microglial IL-1β in the brain.

4.2.3 ATP may be an astrocytic soluble factor that mediates the
α5GABAA receptor regulation of microglial activation
Acting as a neurotransmitter and an inflammatory mediator, ATP has many physiological
and pathological roles in the brain. During neuroinflammation, ATP can be released from
neurons (Bodin and Burnstock, 1998; Gonzalez-Sistal et al., 2007; Xia et al., 2012), activated
astrocytes (Coco et al., 2003; Suadicani et al., 2006), and brain vascular endothelial cells
(Bodin and Burnstock, 1998), regulating the function of brain cells including microglia.
As introduced before, the processing of IL-1β production and secretion in microglia is largely
dependent on the formation of the NALP3 inflammasome, an intracellular protein complex.
In microglia, the key molecular signal that regulates the NALP3 inflammasome is
extracellular ATP, which regulates the inflammasome functions through purinergic receptors
(e.g. P2X7) (Chakfe et al., 2002; Ferrari et al., 1996; Solle et al., 2001). Since one of my
focuses is on IL-1β production and secretion by microglia, I sought to determine if astrocytic

71

α5GABAA receptors regulate microglial activation through the ATP- P2X7 receptor pathway.
As shown in Fig. 3.9B, treating LPS-primed astrocytes with A438079, a specific P2X7
receptor antagonist, increased IL-1β concentration in the media. Notably, treating the isolated
microglia with A438079+LPS-primed ACM further increased the IL-1β concentration in the
media (Fig. 3.12B). These results imply that P2X7 receptors, contrary to previous literature,
have an inhibitory effect on IL-1β secretion. Most importantly, the A438079+LPS-primed
ACM increased the secretion of IL-1β by microglia. This result suggests that ATP may be an
astrocytic soluble factor that mediates the α5GABAA receptor regulation of microglial
activation. Again, this notion requires more experiments for authentication.

4.3 Future studies
In the present study, the primary readout of the effects of α5GABA A receptor signalling on
the microglial activation is the expression and secretion of IL-1β by microglia. However, in
response to systemic inflammation microglia secret a variety of pro- and anti-inflammatory
cytokines, which regulate the process of brain inflammation in a complex manner. Studying
the changes in a wider range of cytokines and inflammatory regulators such as COX-2 and
iNOS in the brain of Gabra5-/- mice is critical for understanding the role of GABAergic
signalling in the regulation of brain inflammation.
On the other hand, during systemic inflammation, microglia in the brain of the Gabra5-/mice could be activated through a variety of stimuli, such as LPS, proinflammatory cytokines
such as TNFα, IL-6 and CCL2/MCP-1, secreted by infiltrating macrophages and
inflammatory mediators released from endothelial cells (Banks et al., 1995; Ek et al., 2001;
Rivest, 2003). In my in vitro study, the neuronal-glial cultures were only challenged by LPS
as the sole inflammatory stimulator. It is important to investigate the cellular and molecular
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mechanism by which α5GABAA receptors regulate microglia activation in response to other
inflammatory cytokines and/or mediators. Treating cultures with stimuli other than LPS may
lead to altered microglial activation profiles, as different stimuli activate different
intracellular pathways.
Although my study showed pharmacological evidence that astrocytes express α5GABAA
receptors and modulate astrocyte activity, definitive proof for the astrocytic expression of
α5GABAA receptors is required. To address this, RT-PCR assay of the α5 subunit mRNA in
highly purified astrocytes should be carried out. In addition, electrophysiological recordings
of GABA-induce current in astrocytes in the absence and presence of L655,708 would also
be useful for verification of the existence of α5GABAA receptors in microglia..
The molecular mechanisms of how α5GABAA receptors affect microglial expression of IL1β still remain to be defined. Results from my experiments implied that astrocytes control
LPS-induced microglial activation through soluble factor(s). Identifying the soluble factor(s)
is crucial for understanding glial cell interaction in the process of brain inflammation. Of
interest is the S100B protein and ATP, as both molecules are secreted by astrocytes and
affect microglia activation (Bianchi et al., 2010; Guerra et al., 2011; Liu et al., 2011).
Future studies should also focus on the molecular mechanisms by which α5GABA A receptor
regulates the intracellular signaling in astrocytes thus modulating microglia activity. Of
interest, determining the effect of α5GABAA receptor inverse agonist on mobilization of
astroctytic intracellular Ca2+ will help establish the signaling pathway.
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4.4 The significance of this study
As stated before, an accumulating amount of evidence indicates that GABA is widely used as
a signalling molecule by various types of cells in the CNS and peripheral organs. New
studies indicate that GABA regulates the function of immune cells in the periphery. The role
of GABAergic signalling in the regulation of brain inflammation has just emerged (Wang et
al., 2012). Another new study indicates that brain ischemia impairs the function of GABA
transporters, increasing extracellular GABA concentration and subsequently increasing
α5GABAA receptor activity, resulting in brain injury (Clarkson et al., 2010). However, the
underlying mechanism of how the increased α5GABAA receptor activity causing brain injury
is unknown. My study showed that the α5GABAA receptor mediated tonic activity in
astrocytes stimulates astrocytic secretion of IL-1β, providing a potential cellular/molecular
mechanism of ischemic brain injury.
My study showed that α5GABAA receptor differentially regulates the production and
secretion of IL-1β by astrocytes and microglia. Specifically, my results imply that in brain
inflammation, the α5GABAA receptor mediates tonic activity in astrocytes, elevating
astrocytic release of IL-1β, but restraining microglial secretion of IL-1β. A full understanding
of the physiological significance of GABAergic regulation of glial cell activity awaits more
studies.
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